Bridger Management, LLC Denali Therapeutics Inc. Transaction History

Bridger Management, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Aug 14, 2018	SELL	$15.25 - $21.02 $4.77 Million - $6.57 Million	-312,500 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$15.04 - $21.45 $4.7 Million - $6.7 Million	312,500	312,500 $4.89 Million

217

115M

142K

90.3K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.84B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Bridger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridger Management, LLC with notifications on news.